Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Study acronym: ENLIGHTEN-4
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 152 to 153
  2. Eligibility criteria expanded, about 19 words
    • Study sites revised (152)
  3. Study sites revised (152)v16
  4. Site details revised at 12 of 152 sitesv15
  5. Trial sites reduced: 161 → 152 locationsv14
Show 5 earlier versionsHide 5 earlier versions
  1. Site details revised at 17 of 161 sitesv13
  2. Study sites: 160 to 161v12
  3. Study sites revised (160)v11
  4. Study sites revised (160)v10
  5. Study sites: 159 to 160v9
  1. Trial sites expanded: 154 → 159 locationsv8
  2. Study sites: 155 to 154v7
  3. Site details revised at 6 of 155 sitesv6
  4. Site details revised at 12 of 155 sitesv5
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 2026 to Feb 9, 2026
    • Site details revised at 155 of 155 sites
    v4
  6. Study sites: 152 to 155v3
  7. Study Status, Referencesv2
  8. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
366 trials monitored
See 16 trials at risk
Obesity
3,909 trials monitored
See 165 trials at risk
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.
Trial Details
NCT Number NCT07353931
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Osteoarthritis, Overweight or Obesity
Related terms Obesity, Osteoarthritis, Overweight
Enrollment 900 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov